Caramel color is widely used in the food industry, and its many variations are generally considered to be safe. It has been known for a long time that THI (2-acetyl-4-(tetrahydroxybutyl)imidazole), a component of caramel color III, causes lymphopenia in animals through sphingosine 1-phosphate (S1P) lyase (S1PL) inhibition. However, this mechanism of action has not been fully validated because THI does not inhibit S1PL in vitro. To reconcile this situation, we examined molecular details of THI mechanism of action using ''smaller'' THI derivatives. We identified a bioactive derivative, A6770, which has the same lymphopenic effect as THI via S1PL inhibition. In the case of A6770 we observe this effect both in vitro and in vivo, and demonstrate that A6770 is phosphorylated and inhibits S1PL in the same way as 4-deoxypyridoxine. In addition, A6770 was detected in rat plasma following oral administration of THI, suggesting that A6770 is a key metabolic intermediate of THI.
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In Brief
Ohtoyo et al. identified A6770 as a novel S1P lyase inhibitor. Mechanistic studies revealed that A6770 is phosphorylated and then directly inhibits S1P lyase. Also, A6770 was detected following oral administration of THI to animals. These results provide a convincing theory about the mechanism of action of THI.
INTRODUCTION
2-Acetyl-4-(tetrahydroxybutyl)imidazole (THI) is a component of ammonia caramel food coloring, which is commonly used in a variety of foods and beverages. Previously, toxicity studies have shown that THI induced lymphopenia and caused mature T cells to accumulate in the thymus, apparently as a result of reduced egress (Gaunt et al., 1977; Evans et al., 1977; Gugasyan et al., 1998) . Although the mechanism had been unclear for a long time, Cyster and co-workers revealed that THI reduces sphingosine 1-phosphate (S1P) lyase (S1PL) activity, resulting in the disruption of S1P gradients between lymphoid organs and blood or lymph that is required for lymphocyte egress from lymphoid organs (Schwab et al., 2005) . Based on these observations, medicinal chemistry efforts targeting S1PL by synthetic analogs of THI were made and led to the discovery of LX2931 (LX3305), which was clinically developed for rheumatoid arthritis (Bagdanoff et al., 2009 (Bagdanoff et al., , 2010 . However, it is still controversial whether THI (and its derivatives) can bind to S1PL directly or whether it first becomes modified in vivo or acts by an indirect mechanism, because THI did not show any in vitro inhibitory activity on S1PL in both cell-free (Schwab et al., 2005; Bagdanoff et al., 2009; Reina et al., 2012) and cell-based systems (Billich et al., 2013a; Loetscher et al., 2013) . Most recently we reported that THI itself shows a weak inhibitory effect in a cell-based system under a vitamin B6 (VB6)-deficient condition, but this solely cannot explain all of the mechanism because of the discrepancy found between the effective concentrations of the in vitro assay (R100 mM) (Ohtoyo et al., 2015) and those found in the plasma of the in vivo study (approximately 0.1-10 mM up to 24 hr following oral administration) (Yu et al., 2010) . It was also reported that THI inhibits pyridoxal kinase (PDXK), which provides pyridoxal 5 0 -phosphate (PLP), a co-factor of various PLP-dependent enzymes including S1PL (Elsinghorst et al., 2015) . However, the corresponding inhibition constants of millimolar range are too high to explain the mechanism. Since the effects of THI and the VB6 analog 4-deoxypyridoxine (DOP) on a rat immune system are quite similar to each other, it has been proposed that THI and DOP share the same mechanism of immunomodulation (Schwab et al., 2005; Houben and Penninks, 1994) . Considering this from a different perspective, we speculated that THI may include a certain structural component in its chemical structure, and that this component (or its modified form) exerts the same biological activity as that of DOP. In this study, therefore, we undertook to synthesize a series of ''smaller'' derivatives of THI with reference to the structure of DOP, and characterized their biological properties. Here, we describe a novel THI derivative, A6770, which could provide an important clue toward completely understanding the mechanism of action of THI.
RESULTS AND DISCUSSION

Discovery of A6770, Which Has a Potent Lymphopenic Effect
To evaluate the potential S1PL inhibitory activity of the synthesized compounds, we utilized a peripheral lymphocyte reduction assay in rodents as systematic in vivo screening because there was no in vitro assay to detect any of the biological effects of THI and its derivatives. Through the derivatization campaign, we unexpectedly found that the substitution at the 4-position of the imidazole core has a significant influence. While either modification of the 1,2,3,4-tetrahydroxybutyl group to a 1,2-dihyroxyethyl group or absolute elimination of a substituent at the position reduced potency, modification to a methanol group resulted in relatively higher lymphopenic activity (Tables S1-S3) . To further characterize this novel compound 1-[4(5)-(hydroxymethyl)-1H-imidazole-2-yl]ethanone (A6770) ( Figure 1A ), we analyzed its pharmacokinetics in parallel with the transition of the peripheral lymphocyte count after oral administration of A6770 to rats. The plasma concentrations peaked 1 hr after dosing and then rapidly decreased ( Figure 1B) , showing that A6770 was rapidly absorbed in rats as THI (Yu et al., 2010) . In contrast to the rapid appearance in plasma, the peripheral lymphocyte number reduced with a nadir at 7 hr after a single dosing of at least 1 mg/kg A6770, and the lymphopenic effect seemed to be saturated with >10 mg/kg A6770 ( Figure 1C ). Around 50% reduction in lymphocyte number may be the maximum effect in this experimental condition (single oral administration to fed rats). As in the cases of THI, there was a temporal difference between plasma A6770 concentrations and the pharmacological response, implying that it could be a common characteristic of this class of compounds. In addition, A6770 had the capability to cause lymphopenia not only in rodents but also in cynomolgus monkeys, suggesting that the pharmacological effect of A6770 is common to multiple species ( Figure S1 ).
A6770 Is a Functional S1PL Inhibitor
We next sought to determine whether the lymphopenic effect observed above is due to S1PL inhibition, which is the mechanism of action of THI. Thymus homogenates derived from rats after administration of A6770 were incubated with [4,5- 3 H] dihydroS1P ([ 3 H]dhS1P, substrate for S1PL), followed by alkaline-chloroform extraction and measurement of radioactivity of aqueous phase, which mainly reflect the remaining [ 3 H]dhS1P.
In contrast to the saturated lymphopenic effect described above, A6770 reduced the amount of [ 3 H]dhS1P degradation dose dependently (Figure 2A ), suggesting that the lymphopenic effect and the reduction in [
3 H]dhS1P degradation activity in thymus are not in a simple proportional relationship. In addition, we observed an increase in S1P in the thymus, which was thought to be attributed to the inhibition of S1P/dhS1P degradation ( Figure 2B ). S1P (or dhS1P) is irreversibly degraded by S1PL into 2-hexadecenal (or 2-hexadecanal) and phosphoethanolamine. At the cellular level, therefore, inhibition of this enzyme is expected to cause intracellular accumulation of S1P and dhS1P. On the other hand, cellular contents of these sphingoid base 1-phosphates are regulated not only by S1PL but also by sphingosine kinases (SPHK) and S1P phosphohydrolases (SPP). Hence, we investigated the effect of A6770 on the overall pattern of sphingolipid metabolism by using Figure 2C ). The increase in dhS1P/S1P suggests that A6770 inhibits degradation of dhS1P/S1P while the amounts of dhSph/Sph and ceramide remain largely unaltered. The decrease in glycerophospholipids suggests that A6770 also inhibits the multi-step conversion of the sphingosine backbone into glycerophospholipids, which involves among others the S1PL reaction. Taken together, these results suggest that A6770 leads to S1PL inhibition rather than SPHK activation or SPP inhibition. Because S1PL appears to modulate T cell circulation, partial inhibition of S1PL has been proposed as a therapeutic modality, especially in T cell-dependent inflammatory processes including autoimmune disease (Bagdanoff et al., 2009 (Bagdanoff et al., , 2010 Vogel et al., 2009 ). In fact, previous studies showed the therapeutic relevance of S1PL using experimental autoimmune encephalomyelitis (EAE), (B and C) A6770 induces reductions in peripheral lymphocyte number in rats. A6770 was orally administered to rats at indicated doses under a fed condition. Peripheral blood was collected at the indicated time points and the plasma concentrations of A6770 were quantified by LC-MS/MS (B), and the lymphocyte was counted via a hematology system (C). The relative lymphocyte number compared with vehicle was calculated at each point. Data represent the mean ± SD (n = 3 rats per group).
an animal model of multiple sclerosis (Billich et al., 2013b; Weiler et al., 2014 ). Therefore, we tested A6770 for its efficacy to suppress EAE development in mice. While vehicle treatment showed the progression of disease severity, mice treated with 300 mg/kg A6770 were significantly protected from EAE development (Figure S2) . These data suggest that A6770 is a functional S1PL inhibitor with some therapeutic potential.
A6770 Inhibits S1PL in a VB6-Antagonistic Manner Through the various in vitro analyses of A6770, we found that A6770 also inhibits pyridoxine uptake into cells and PDXK (Figures S3A and S3B) . Since these in vitro characteristics of A6770 were quite similar to those of DOP, we tried to determine whether A6770 inhibits S1PL in a VB6-antagonistic manner. It is known that DOP is phosphorylated by PDXK to form DOP 5 0 -phosphate (DOP-P), which competes for the active site of various PLP-dependent apoenzymes (Trakatellis et al., 1997) . Firstly, to confirm that A6770 can also be phosphorylated in the same way, we conducted a cell-free phosphorylation experiment using recombinant PDXK and high-performance liquid chromatography (HPLC) analysis. In this system, it was previously observed that DOP was converted to DOP-P (Ohtoyo et al., 2015) . After incubation of A6770 with PDXK we detected the shifted peak, which was identified as [2-acetyl-1H-imidazole-4(5)-yl]methoxyphosphate (A6770-P) by the consistency of retention time with chemically synthesized A6770-P (FigFigure 2 . S1PL Inhibition by A6770 ure 3A). Also in a rat in vivo study, A6770-P was detected in the thymus homogenate after oral administration of A6770, showing that the conversion from A6770 to A6770-P can occur even in vivo ( Figures 3B and 3C ). Secondly, we examined the inhibitory activity of A6770-P on S1PL by using a membrane fraction (MF) derived from cells cultured in a VB6-deficient medium (Ohtoyo et al., 2015) . This MF includes a decreased amount of holoenzyme (with PLP, active form) and an increased amount of apoenzyme (without PLP, inactive form), and therefore showed slight dhS1P degradation activity, whereas the enzymatic activity was restored by the addition of PLP. In this assay, restoration of enzymatic activity was inhibited by the addition of R0.1 mM A6770-P prior to PLP, while unphosphorylated A6770 did not show any inhibitory effects even at the concentration of 1 mM ( Figure 3D) . Surprisingly, the inhibitory activity of A6770-P was much stronger than that of DOP-P, implying the possibility that A6770-P is the most potent direct S1PL inhibitor ever known, although the specificity of A6770-P for other PLP-dependent enzymes must be carefully investigated in future.
We note that unlike FTY720, neither A6770 nor A6770-P showed binding to S1P 1 in the [
35 S]GTP-g-S binding assay, indicating that the lymphopenic effect of A6770/A6770-P is not mediated by functional antagonism of S1P 1 ( Figure S3C ).
A6770 Is a Key Metabolic Intermediate of THI
All the results obtained so far brought to us the expectation that THI might exert its biological effects through the conversion to A6770, which is subsequently phosphorylated into A6770-P and inhibits S1PL in cells. To investigate this possibility, we analyzed the pharmacokinetics of A6770 as a surrogate of
Cell Chemical Biology 23, 1-6, May 19, 2016 3 A6770-P as well as the pharmacokinetics of THI, in parallel with a transition of the peripheral lymphocyte number after oral administration of THI to rats. As expected, A6770 was definitely detected in plasma and showed a slow appearance with a peak at R7 hr after THI administration ( Figure 4B ). The tendency of the time-dependent transition was consistent with that of the lymphopenic effect, although the peak plasma concentrations of THI were observed approximately 1 hr after dosing, as with previous reports (Figures 4A and 4C) (Bagdanoff et al., 2010; Yu et al., 2010) . The detected concentrations of A6770 (<0.32 mg/ml) were extremely low compared with those of THI administered, but it could be speculated that lymphopenia occurs even if the plasma A6770 are at such a low level. This is because 1 mg/kg dosing of A6770 itself resulted in a plasma concentration (%0.32 mg/ml) similar to that above, while a >30% (A) A6770 is phosphorylated by PDXK. A6770 was incubated with or without recombinant PDXK, followed by an HPLC analysis. Chemically synthesized A6770-P was analyzed for reference.
(B and C) A6770-P is detected in rat thymus after oral administration of A6770. Thymus was collected at the indicated time points and the concentrations of A6770 (B) or A6770-P (C) were measured by LC-MS/MS. Data represent the mean ± SD (n = 3 rats per group).
(D) A6770-P but not A6770 inhibits S1PL in a cellfree assay. Test compounds were added to the apoenzyme-enriched MF and then incubated prior to the addition of 5 mM PLP (except for PLP(À)). reduction in lymphocyte number was observed ( Figures 1B and 1C ). In addition, the appearance of A6770 after THI administration was also observed in cynomolgus monkeys ( Figure S4 ). With respect to the marked discrepancy between the plasma THI concentration and the pharmacological response, another group speculated that the building up of the lymphoid S1P concentration following inhibition of the S1PL may be a timeconsuming step (Yu et al., 2010) . However, our findings raise the novel hypotheses that (1) conversion to A6770 and subsequent phosphorylation into A6770-P are essential for THI to exert its biological effect, and (2) the slow appearance of A6770 in plasma is a major cause of the unsynchronized pharmacokinetic/ pharmacodynamic relationship of THI. If these suppositions are true, the question remains as to what prevails in the in vivo conversion route from THI into A6770. Our preceding data suggest that some kind of enterobacterium is likely to be involved in this conversion, because pre-treatment of antibiotics prior to the THI administration canceled both the A6770 appearance in plasma and the lymphopenic effect, without affecting the transition of the plasma concentration of THI ( Figures 4A-4C ). Taking together this finding and the fact that THI causes lymphopenia in rats even via parenteral administrations (Gobin and Paine, 1989) , it is speculated that THI undergoes enterohepatic circulation, which could be the reason for the slow appearance of A6770 in plasma. On the other hand, no evidence for the metabolism of THI was obtained in the past study in which [
14 C]THI was orally administered to rats (Phillips and Paine, 1990) . We estimate that (1) the slow appearance of A6770, (2) low conversion efficacy from THI to A6770, and (3) the detection method of low sensitivity (thin-layer chromatography [TLC] and autoradiography) could be the reason for this inconsistency, but further verification studies will be needed to fully address the THI-to-A6770 conversion mechanism.
In conclusion, we discovered a novel S1PL inhibitor, A6770, and clarified its mode of inhibition both in vitro and in vivo. Furthermore, our data suggest that THI acts as a prodrug of A6770/A6770-P. We hope our results will contribute greatly to the complete understanding of the mechanism of action of THI.
SIGNIFICANCE
Although Cyster and co-workers reported S1PL inhibition by THI in 2005, the mechanism of inhibition has been not validated so far because many researchers failed to detect S1PL inhibition by THI in vitro. Therefore, it has been merely speculated, without any supportive data, that THI may be converted into unidentified active metabolites. In this regard, we have demonstrated strong evidence for the first time. Our findings present a convincing theory whereby THI exerts its biological effect through the in vivo conversion to A6770. In addition, the potent S1PL inhibition activity of A6770/A6770-P provides a new tool compound for investigation of the effect of S1PL inhibition in various biochemical, cellular, and animal models.
EXPERIMENTAL PROCEDURES
Test Compounds DOP was purchased from Sigma. DOP-P, THI, A6770, and A6770-P were synthesized in-house, and the detailed synthetic protocols are provided in Supplemental Experimental Procedures.
Animals, Cells, and Other Materials
All animal experiments were carried out according to the guidelines provided by the Institutional Animal Care and Use Committee of Daiichi Sankyo. C57BL/6NCrlCrlj mice and LEW/CrlCrlj rats were from Charles River Laboratories. Cynomolgus monkeys were from Hamri and LSG. Mouse thymic nurse cell line IT-79MTNC3 was from the Human Science Research Resources Bank. VB6-deficient DMEM was a custom order medium produced by the Cell Science & Technology Institute. [4,5- 3 H]-Labeled sphingolipids and 3 H-labeled pyridoxine were made by American Radiolabeled Chemicals. Non-labeled sphingolipids and FB1 were from Enzo Life Sciences.
In Vivo Evaluations following Oral Administration of Test Compounds
Test compounds were orally administered per gavage at each dose to rats under a fed condition or to monkeys under a fasted condition. An antibiotics solution was given to rats ad libitum from 5 days before the dosing of THI until the time they were euthanized. Blood and/or thymus were collected at each time point and the concentrations of compounds in these samples were measured by liquid chromatography-tandem mass spectrometry (LC-MS/ MS). Also, each blood sample collected from rats or monkeys was used for lymphocyte counting. In addition, thymus homogenates were prepared and used for [ 3 H]dhS1P degradation assay.
was added to thymus homogenate and incubated at 37 C for 1 hr.
Negative control sample reactions were performed on ice. The reaction mixture was mixed with 0.2 N NaOH and chloroform, followed by centrifugation (8,400 3 g, 3 min). Radioactivities of the aqueous phase were measured by a liquid scintillation counter.
[
H]dhSph Labeling Analysis
IT-79MTNC3 cells pre-treated with 25 mM FB1 were incubated for 4.5 hr in the presence of increasing concentrations of A6770 in conventional/VB6-deficient DMEM containing 0.1% BSA, followed by labeling with [ 3 H]dhSph for 0.5 hr.
Lipids were extracted from cells and separated by TLC, and visualized by autoradiography.
In Vitro Phosphorylation Analysis Purified recombinant human PDXK was mixed with A6770 in the presence of 1 mM ATP, and incubated at 37 C for 1 hr. HPLC analysis was performed as previously described (Ohtoyo et al., 2015) . (A-C) THI was orally administered to rats at 50 mg/kg under a fed condition, with or without pre-administration of antibiotics. At the indicated time points, plasma concentrations of THI (A) or A6770 (B) were measured by LC-MS/MS, and the peripheral lymphocyte number was counted via a hematology system (C). The relative lymphocyte number compared with vehicle treatment was calculated at each point. Data are presented as mean ± SD (n = 3 rats per group).
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Cell-Free S1PL Enzymatic Assay MF as an enzyme source were prepared as previously described (Ohtoyo et al., 2015) . Test compounds were pre-incubated with MF for 0.5 hr at room temperature. PLP (final 5 mM) was then added and further incubated for 0.5 hr, followed by the addition of [ 3 H]dhS1P and incubation at 37 C for 1 hr. Subsequent steps were carried out in the same manner as for the [ 3 H]dhS1P degradation assay described above. Billich, A., Baumruker, T., Beerli, C., Bigaud, M., Bruns, C., Calzascia, T., Isken, A., Kinzel, B., Loetscher, E., Metzler, B., et al. (2013b) . Blood was collected at the indicated time points and the plasma concentrations of A6770 were quantified by LC-MS/MS. This data represents the mean SD (n = 4 for 10 mg/kg and n = 3 for 100 mg/kg, respectively). (B) Peripheral blood was collected at the indicated time points and the lymphocyte number was counted using a hematology system. The relative lymphocyte number compared to pre-treatment was calculated at each point. This data represents the mean SD (n = 3). In this figure, individual dose data were obtained from separate experiments. 
SUPPLEMENTAL INFORMATION
Time after THI administration (h)
Chemistry
All starting materials and synthesis reagents were obtained commercially. Flash column chromatography was performed with Biotage FLASH Si or YAMAZEN Hi-Flash packed columns. Reverse phase preparative HPLC was performed with a Develosil Combi-RP-5 column (28 mm 100 mm, Nomura) using 0.1% HCO 2 H /H 2 O and 0.1% HCO 2 H /CH 3 CN as eluent at a flow rate of 25 ml/min. The 1 H NMR spectra were recorded on a JEOL JNM-EX-400 spectrometer, and chemical shifts are given in ppm (δ) from tetramethylsilane as an internal standard. The spectral splitting patterns are designated as follows: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet. The mass spectra were recorded on a SCIEX API-150EX spectrometer (ESI) and a JEOL JMS-HX110 spectrometer (FAB). Elemental analysis was performed using a PerkinElmer CHNS/O 2400II, a Leco CHNS-932 and a YOKOKAWA analysis IC7000RS. DOP-P and THI were internally synthesized with reference to previous reports (Long and Morrison, 1954; Cliff and Pyne, 1997) . Detailed synthetic protocols for A6770 and A6770-P are described later.
Animals, cells and other materials
All animal experiments were carried out according to the guidelines provided by the Institutional Animal Care and Use Committee of Daiichi Sankyo Co., Ltd. C57BL/6NCrlCrlj mice (male, 6 weeks old) and LEW/CrlCrlj rats (male, 3 weeks old) were purchased from Charles River Laboratories Japan, and were used after a 1-week habituation period. Cynomolgus monkeys (female, 7−9 years old) were supplied from Hamri and LSG. Mouse thymic nurse cell line IT-79MTNC3 was obtained from Human Science Research Resources Bank, and was passaged in a conventional DMEM supplemented with 10% FBS at 37ºC with 5% CO 2 in a humidified atmosphere. VB6-deficient DMEM was a custom order medium produced by Cell Science & Technology Institute. [4,5-3 H]-labeled sphingolipids and [ 3 H]-labeled pyridoxine were made by American Radiolabeled Chemicals. [ 35 S]GTPγ-S (1 mCi/ml, > 1000 Ci/mmol) was purchased from GE Healthcare. Non-labeled sphingolipids and fumonisin B1 (FB1) were from Enzo Life Sciences.
Administration and sample preparation for PK analysis A6770 was orally administered to rats per gavage at 1, 10 and 100 mg/5 ml/kg in 0.5% methyl cellulose (MC) under a fed condition, or to monkeys per gavage at 3, 10 and 100 mg/5 ml/kg in 0.5% MC under a fasted condition. THI was orally administered to rats per gavage at 30 and 100 mg/5 ml/kg in 0.5% MC under a fed condition, or to monkeys per gavage at 50 mg/ml/kg in 0.5% MC under a fasted condition. An antibiotics solution (mixture of 1 mg/ml of Penicillin G potassium salt (Sigma) and 2 mg/ml of streptomycin sulfate salt (Sigma)) was given to rats ad libitum from five days before the dosing of THI until the time they were euthanized. Blood was collected at each time point and plasma samples were obtained by centrifugation of the blood at 4ºC. Thymus was collected at each time point and the homogenate samples were prepared by adding water and then homogenizing. All samples were stored at −80ºC until analysis. Peripheral lymphocyte counting Each blood sample collected from the rats or monkeys was immediately put into an evacuated blood collection tube coated with anticoagulant (EDTA-2K) (Nipro), and followed by the lymphocyte counting of each blood sample using an ADVIA2120 (Siemens) at Daiichi Sankyo RD Novare Co., Ltd.
Supplemental Experimental Procedures
[ 3 H]dhS1P degradation assay To prepare thymus homogenates, thymus samples collected from rats were added to a homogenization buffer [50 mM HEPES-NaOH (pH 7.4), 150 mM NaCl, 10% Glycerol, 1 mM EDTA, 1 mM dithiothreitol, cOmplete protease inhibitor cocktail (Roche)] and zirconia ball, then vigorously agitated by a TissueLyzer (QIAGEN). Tissue suspensions were sonicated with a tip-type sonicator, centrifuged (1,000 g, 3 min), and the supernatants (thymus homogenates) were flash frozen in liquid N 2 and stored at −80ºC. In order to evaluate dhS1P degradation activity, 0.01 μCi per test of [ 3 H]dhS1P was added to thymus homogenate (12.5 μg protein per test) and incubated at 37ºC for 1 h in 50 μl of reaction buffer [100 mM potassium phosphate (pH 7.4), 25 mM sodium fluoride, 5 mM sodium orthovanadate, 1 mM EDTA, 1 mM dithiothreitol, 0.1% Triton X-100, 2 μM dhS1P]. Negative control sample reactions were performed on ice. The reaction mixture was mixed with 50 μl of 0.2N NaOH and 100 μl of chloroform by using an electric vortex mixer, followed by centrifugation (8,400 g, 3 min ). An aliquot of the aqueous phase containing [ 3 H]dhS1P was collected, and the radioactivity was measured by a liquid scintillation counter (Aloka).
Quantification by LC-MS/MS
HPLC was performed using an Acquity UPLC system (Waters) and an ACQUITY BEH Amide column (2.1 mm 150 mm, 1.7 µm, Waters) under the following conditions: column oven temperature, 40ºC; sample cooler temperature, 10ºC; injection volume, 7.5 µL; wash solution, purified water, gradient elution using solvent D (acetonitrile/water = 950/50, v/v containing 5 mM ammonium acetate) and solvent C (acetonitrile/water = 50/950, v/v containing 5 mM ammonium acetate), at a flow rate of 400 µl/min. MS/MS analysis was performed using API 4000 or API 5000 systems (Applied Biosystems/ MDS SCIEX) under the following conditions: ionization mode, ESI-negative; curtain gas and set value, N 2 and 20 psi; collision gas and set value, N 2 and 5 arbitrary unit; ion source gas 1 and set value, Air and 60 psi; ion source gas 2 and set value, Air and 80 psi; ionspray voltage, −4500 V; ion source temperature, 600ºC; interface heater, ON. Monitoring ions are described in below. LC-MS/MS analyses were performed at Daiichi Sankyo RD Novare Co., Ltd.
EAE model
Four mg/ml of myelin oligodendrocyte glycoprotein35-55 (MOG35-55, Peptide Institute) dissolved in saline was mixed with the same volume of Freund's incomplete adjuvant (Difco Laboratories) supplemented with 8 mg/ml M. Tuberculosis H37 Ra (Difco Laboratories), resulting in formation of the emulsion. This emulsion (50 μl per injection) was subcutaneously injected into both flanks of the mouse. After that, 0.5 μg/ml of Pertussis Toxin, Bordetella pertussis (Calbiochem) dissolved in saline (200 μl) was administered into the tail vein (Day 0). All mice were weighed every day from Day 0 to Day 19. Each dose of A6770 (or vehicle) was dissolved in 0.5% MC at the ratio of 1 ml/100 g weight, and was orally administered to the mice. Clinical observations were scored every day after Day 7 according to the criteria as follows: 0, no abnormality; 1, flaccid tail; 2, paralysis of one hind limb; 3, paralysis of both hind limbs; 4, tetraplegia; 5, dead.
Statistics
Statistical significance in EAE study (cumulative score) was calculated by a nonparametric Dunnett test (joint ranking) using REDPOST (SAS System Release 8.2).
[ 3 H]dhSph labeling analysis Subconfluent IT-79MTNC3 cells were harvested and suspended in a conventional DMEM containing 10% FBS and 25 μM FB1, then seeded into 12-well tissue culture plates at 1 10 5 cells per well and incubated overnight at 37ºC with 5% CO 2 . On the next day, the medium was discarded, and the cells were further incubated for 4.5 h in the presence of increasing concentrations of A6770 in conventional or VB6-deficient DMEM containing 0.1% BSA. In order to trace sphingolipid metabolism, cells were labeled with 0.5 μCi per well of [ 3 H]dhSph for 0.5 h. Cells were washed once and subjected to lipid extraction by chloroform/methanol/HCl (100:200:1, v/v/v) and mixed in a vortex mixer, followed by the addition of chloroform and 1% KCl. After phase separation, extracted lipids were further separated by TLC on Silica Gel 60 high performance TLC plates (Merck) with a 1-butanol/acetic acid/H 2 O mixture (3:1:1, v/v/v) and visualized by autoradiography (Ikeda et al., 2005) .
In vitro phosphorylation analysis
Purified recombinant human PDXK (final 4 μg/ml) was mixed with 200 μM of A6770 in the presence of 1 mM ATP in a 100 μl solution, and incubated at 37ºC for 1 h. After the reaction, HPLC analysis was performed with reference to the previous report (Rybak and Pfeiffer, 2004) using an Agilent 1100 HPLC system and a Discovery BIO Widepore C18 column (150 2.1 mm, 3 μm) under the following conditions: sample injection volume, 10 μl; isocratic elution with 50 mM sodium phosphate (pH 3.1), and 0.2% acetonitrile, at a flow rate of 0.5 ml/min with the detection of absorbance at 280 nm.
Cell-free S1PL enzymatic assay Membrane fractions as an enzyme source were prepared as described in the previous report (Ohtoyo et al., 2015) . To evaluate dhS1P degradation activity, membrane fractions (10 µg protein per test) and PLP (ALEXIS Biochemicals) were pre-incubated for 0.5 h at room temperature, followed by the addition of 0.01 µCi per test of [ 3 H]dhS1P and incubation at 37ºC for 1 h in 50 µl of reaction buffer. Subsequent steps were carried out in the same manner as the previous section ([ 3 H]dhS1P degradation assay). For the inhibition study, various concentrations of test compounds were pre-incubated with membrane fractions for 0.5 hprior to the addition of PLP (final 5 µM).
Pyridoxine uptake assay Subconfluent IT-79MTNC3 cells were harvested and suspended in a conventional DMEM containing 10% FBS, then seeded into 96-well tissue culture plates at 2 10 4 cells per well and incubated overnight at 37ºC with 5% CO 2 . On the next day, cells were washed twice with PBS, and were pre-incubated in PBS for 10 min. After that, [ 3 H]pyridoxine (0.55−1.11 TBq/mmol, final 320 nM) was added to cells, followed by further incubation for 10 min in the absence or presence of various concentrations of test compounds. After the reaction, washed cells were lysed by the addition of 1N NaOH, then the lysates were neutralized by 1N HCl. Radioactivity corresponding to the amount of [ 3 H]pyridoxine incorporated into the cells was measured by a liquid scintillation counter (Aloka).
PDXK inhibition assay
Pyridoxal (substrate, final 16 µM) and recombinant PDXK (0.5 µg per test) were mixed in 200 µL of PDXK reaction buffer [0.1 M potassium phosphate (pH 6.4), 1 mM ATP, 0.1 mM ZnCl 2 , 0.1% BSA] in the absence or presence of various concentrations of test compounds. The mixture was incubated at 37ºC for 1 h, followed by the addition of 40 µL of hydroxylamine. Fluorescence intensity (Ex/Em = 355/460 nm) corresponding to the amount of the product (PLP) was measured by a Wallac ARVO SX 1420 Multilabel Counter (PerkinElmer). See also the reference (Hanna et al., 1997) .
[ 35 S]GTPγ-S binding assay
Serial dilutions of test compounds were made by dissolving them in methanol containing 20 mM of pyrrolidine (pyrrolidine solution) for S1P and A6770 or in assay buffer [50 mM HEPES-NaOH (pH 7.5), 100 mM NaCl, 5 mM MgCl 2 , 0.05 mg/ml saponin] for A6770-P, respectively. First, 58 μl (56 μl for A6770-P) of assay buffer and 10 μl of 40 μM GDP solution (22.2 μg/ml GDP, 8.35 μg/ml DTT in assay buffer) were added to the wells of a 96-well microplate (SUMILON PROTEOSAVE 96 U plate, SUMITOMO BAKELITE). Next, 2 μl of the diluted test compounds or pyrrolidine solution (for negative control) was added to the individual wells. In the case of A6770-P, 2 μl of pyrrolidine solution was further added so that buffer conditions of all the wells were uniform. Then the assay was initiated by the addition of 10 μl of 3.5 nM [ 35 S]GTPγ-S followed by the addition of 20 μl of 0.5 mg/ml membrane fraction derived from CHO-K1 cells expressing human S1P 1 , and mixed well. After 60 min of incubation at room temperature, membrane fractions were immediately collected onto a UniFilter-96, GF/C (PerkinElmer) by a cell harvester. The filter bound with the membrane was washed, fully dried, and the radioactivity was measured by a TopCount NXT (PerkinElmer). See also the reference (Im et al., 2001) .
[1-(Ethoxymethyl)imidazol-4-yl]methanol
LiAlH 4 , THF 0 °C to rt To a cooled (0ºC), stirred suspension of LiAlH 4 (3.85 g, 93.2 mmol) in THF (200 ml) was added dropwise a solution of methyl 1-(ethoxymethyl)imidazole-4-carboxylate (39.4 g, 213.9 mmol) in THF (150 ml) over 0.5 h. After being stirred at that temperature for 0.5 h, the reaction was quenched by addition of H 2 O (3.85 ml), 15% aq. NaOH (3.85 ml), and H 2 O (11.6 ml), and the stirring was continued for 10 h at room temperature. The mixture was filtered through a Celite pad and the resulting filtrate was concentrated under reduced pressure to give [1-(ethoxymethyl) imidazol-4-yl]methanol (21.0 g, 63%) as a light brown oil, which was used without purification. 1 H-NMR (CDCl 3 ) δ: 1.19 (3H, t, J = 7.1 Hz), 3.46 (2H, q, J = 7.1 Hz), 4.62 (2H, s), 5.25 (2H, s), 7.00 (1H, s), 7.56 (1H, s). To a stirred solution of methyl 1H-imidazole-4-carboxylate (3.00 g, 23.8 mmol) in MeCN (100 ml) were added TEA (6.63 ml, 47.6 mmol) and chloromethyl methyl ether (3.28 ml, 43.5 mmol), and the solution was refluxed for 10 h. After being cooled to room temperature, the reaction mixture was quenched by addition of H 2 O and extracted with EtOAc. The extract was washed with brine, dried over NaSO 4 , and concentrated under reduced pressure. The resulting residue was purified by flash chromatography on silica gel with hexane/EtOAc (9:1 to 0:1, v/v) as eluent to give methyl 1-(ethoxymethyl)imidazole-4-carboxylate (2.67 g, 61%) as a colorless oil. To a cold (-78ºC), stirred solution of [1-(ethoxymethyl) imidazol-4-yl]methoxytriethylsilane (665 mg, 2.46 mmol) in THF (20 ml) was added n-butyl lithium (2.64 M in n-hexane, 1.50 ml, 3.96 mmol) under an argon atmosphere. After being stirred at that temperature for 0.5 h, N-methoxy-N-methylacetamide (507 mg, 4.92 mmol) was added to the mixture, and the resulting mixture was allowed to warm to room temperature while stirring. After 17 h of stirring, the reaction mixture was quenched by addition of sat. NH 4 Cl and extracted with EtOAc. The separated extract was washed with brine, dried over MgSO 4 , and concentrated under reduced pressure. To a stirred solution of [1-(ethoxymethyl) imidazol-4-yl]methanol (0.520 g, 3.33 mmol) in CH 2 Cl 2 (30 ml) were added TEA (1.16 ml, 8.32 mmol), TESCl (1.12 ml, 6.66 mmol), and a catalytic amount of DMAP. After being stirred for 17 h, the mixture was diluted with H 2 O and extracted with CHCl 3 . The extract was washed with brine and dried over Na 2 SO 4 . Evaporation of the solvent followed by purification by flash chromatography on silica gel with hexane/EtOAc (9:1 to 1:4, v/v) as eluent to give [1-(ethoxymethyl) imidazol-4-yl]methoxytriethylsilane (665 mg, 74%) as a colorless oil. -1H-imidazol-4-yl)methyl dihydrogen phosphate (A6770-P) 
Synthesis of (2-Acetyl
tert-Butyldiphenyl-[[1-(2-trimethylsilylethoxymethyl)imidazol-4-yl]methoxy]silane
TBDPSCl, TEA DMAP, CH 2 Cl 2
To a stirred solution of [1-(2-trimethylsilylethoxymethyl) imidazol-4-yl]methanol (100 g, 0.438 mol) in CH 2 Cl 2 (1 L) were added triethylamine (122 ml, 0.876 mol), 4-(N,Ndimethylamino)pyridine (5.35 g, 0.044 mol), and tert-butyldiphenylsilyl chloride (149 ml, 0.569 mol) successively. After being stirred for 1 day, the mixture was washed with H 2 O, dried over Na 2 SO 4 , and concentrated under reduced pressure. The resulting residue was purified by flash column chromatography on silica gel with hexane/EtOAc (4:1 to 1:1, v/v) as eluent to give tert-butyldiphenyl-[ [1-(2-trimethylsilylethoxymethyl) To a cold (-78ºC), stirred solution of tert-butyldiphenyl-[ [1-(2-trimethylsilylethoxymethyl) imidazol-4-yl]methoxy]silane (30 g, 63.4 mmol) was added dropwise n-butyllithium (2.66 M in n-haxane, 36.2 ml, 96.4 mmol) . After being stirred at that temperature for 0.5 h , to the mixture was added dropwise N-methoxy-Nmethylacetamide (13.1 ml, 129 mmol) and the resulting mixture was allowed to warm to 0ºC with stirring. The mixture was quenched with sat. NH 4 Cl and extracted with EtOAc. The extract was washed with brine, dried over Na 2 SO 4 , and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel with hexane/EtOAc (19:1 to 7:3, v/v) to give 1-[4-[[tert-butyl(diphenyl) 
